Parallel Advisors, LLC Clovis Oncology, Inc. Transaction History

Parallel Advisors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 28, 2022	SELL	$1.43 - $3.14 $4,168 - $9,153	-2,915 Reduced 96.68%	100 $0
Q4 2021 Jan 20, 2022	BUY	$2.7 - $4.76 $7,870 - $13,875	2,915 Added 2915.0%	3,015 $8,000
Q1 2021 Apr 23, 2021	SELL	$4.81 - $10.34 $3,847 - $8,272	-800 Reduced 88.89%	100 $1,000
Q2 2020 Jul 16, 2020	BUY	$5.69 - $9.69 $569 - $969	100 Added 12.5%	900 $6,000
Q2 2019 Aug 05, 2019	SELL	$12.81 - $25.67 $627 - $1,257	-49 Reduced 5.77%	800 $12,000
Q1 2019 May 01, 2019	SELL	$17.66 - $30.28 $5,298 - $9,084	-300 Reduced 26.11%	849 $21,000
Q4 2018 Feb 05, 2019	BUY	$11.63 - $32.67 $13,362 - $37,537	1,149 New	1,149 $20,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Parallel Advisors, LLC with notifications on news.